1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Drug Substance Manufacturing
  6.  » Using GPEx® Technology for Development & Biomanufacturing of Difficult-to-express Proteins

Using GPEx® Technology for Development & Biomanufacturing of Difficult-to-express Proteins

Summary: Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies looking to improve speed and efficiency of biologic development. Cell line development is a critical step in the development process, impacting protein quality, manufacturing scalability/efficiency and timelines. The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines. The GPEx platform is particularly beneficial for complex proteins, such as multi-specific antibodies, unique protein fusions, bioconjugates (including Antibody Drug Conjugates), proteins requiring cleavage and proteins requiring other post-translational modification not typically performed by CHO cells.

Click here to download the Webinar